一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> ACS Biomaterials Science & Engineering >>article
ACS Biomaterials Science & Engineering

ACS Biomaterials Science & Engineering

IF: 5.4
Download PDF

CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer

Published:27 July 2021 DOI: 10.1038/s41419-021-04027-6 PMID: 34315855
Hanqi Lei,?Zifeng Wang,?Donggen Jiang,?Fang Liu,?Meiling Liu,?Xinxing Lei,?Yafei Yang,?Bin He,?Min Yan,?Hai Huang,?Quentin Liu,?Jun Pang

Abstract

Androgen receptor (AR) signaling inhibitors provide limited survival benefits to patients with prostate cancer (PCa), and worse, few feasible genomic lesions restrict targeted treatment to PCa. Thus, a better understanding of the critical dependencies of PCa may enable more feasible therapeutic approaches to the dilemma. We performed a kinome-scale CRISPR/Cas9 screen and identified cyclin-dependent kinase 12 (CDK12) as being conservatively required for PCa cell survival. Suppression of CDK12 by the covalent inhibitor THZ531 led to an obvious anti-PCa effect. Mechanistically, THZ531 downregulated AR signaling and preferentially repressed a distinct class of CDK12 inhibition-sensitive transcripts (CDK12-ISTs), including prostate lineage-specific genes, and contributed to cellular survival processes. Integration of the super-enhancer (SE) landscape and CDK12-ISTs indicated a group of potential PCa oncogenes, further conferring the sensitivity of PCa cells to CDK12 inhibition. Importantly, THZ531 strikingly synergized with multiple AR antagonists. The synergistic effect may be driven by attenuated H3K27ac signaling on AR targets and an intensive SE-associated apoptosis pathway. In conclusion, we highlight the validity of CDK12 as a druggable target in PCa. The synergy of THZ531 and AR antagonists suggests a potential combination therapy for PCa.

Substances (6)

Materials
Procduct Name CAS Molecular Formula Supplier Price
Hydrocortisone 50-23-7 C21H30O5 944 suppliers $25.00-$15100.00
Hydrocortisone 50-23-7 C21H30O5 944 suppliers $25.00-$15100.00
Hydrocortisone 50-23-7 C21H30O5 944 suppliers $25.00-$15100.00
Hydrocortisone 50-23-7 C21H30O5 944 suppliers $25.00-$15100.00
Hydrocortisone 50-23-7 C21H30O5 - Inquiry
Hydrocortisone 50-23-7 C21H30O5 - Inquiry

Similar articles

IF:98.4

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

The Lancet Neil E Fleshner, M Scott Lucia,etc Published: 24 March 2012
IF:3.6

Virtual Screening and Biological Evaluation of Natural Products as Novel VPS34 Inhibitors that Modulate Autophagy

ChemMedChem Xiaowen Feng, Baoming Wu,etc Published: 22 November 2024
IF:13

Dutasteride: a review of its use in the management of prostate disorders.

Drugs Susan J Keam, Lesley J Scott,etc Published: 1 January 2008
顺平县| 体育| 嘉荫县| 商河县| 商洛市| 鄂托克旗| 墨脱县| 汉阴县| 连山| 张掖市| 环江| 扶余县| 辰溪县| 襄城县| 南乐县| 晋州市| 梓潼县| 城口县| 静安区| 屯门区| 昌都县| 兰溪市| 蒙山县| 衡南县| 石家庄市| 丹巴县| 西城区| 灵山县| 九台市| 旺苍县| 利津县| 大荔县| 东乌珠穆沁旗| 进贤县| 固始县| 临沧市| 宜兰市| 桑植县| 深水埗区| 健康| 武汉市|